HC Wainwright Reiterates Buy Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 456.17% from the company’s current price.

Separately, Alliance Global Partners lowered their target price on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research note on Tuesday, August 13th.

Barinthus Biotherapeutics Price Performance

Shares of BRNS opened at $0.90 on Tuesday. The firm has a market cap of $35.55 million, a PE ratio of -0.60 and a beta of -0.59. The stock’s fifty day moving average price is $1.28 and its two-hundred day moving average price is $1.51. Barinthus Biotherapeutics has a 1 year low of $0.81 and a 1 year high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The company had revenue of $14.97 million for the quarter. During the same quarter last year, the firm posted ($0.37) EPS. Sell-side analysts anticipate that Barinthus Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several large investors have recently made changes to their positions in BRNS. Catalina Capital Group LLC bought a new position in Barinthus Biotherapeutics in the second quarter worth approximately $25,000. Ipswich Investment Management Co. Inc. purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter valued at $32,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Barinthus Biotherapeutics during the 1st quarter valued at $1,292,000. DC Funds LP purchased a new position in Barinthus Biotherapeutics in the 1st quarter worth $1,528,000. Finally, Alphabet Inc. acquired a new stake in Barinthus Biotherapeutics during the 2nd quarter worth about $2,119,000. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.